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INTRODUCTION
Latrophilin-1 (LPHN1) is an adhesion G-protein-
coupled receptor, which participates in control of calcium 
signalling and exocytosis in vertebrate neurons and 
neuroendocrine cells. LPHN1 is highly expressed in the 
brain, detected at low levels in some other tissues, and 
reported as absent from blood [1]. Interestingly, this 
protein and its homologues appear to be upregulated in 
malignant cells: LPHN1 is found in non-small cell lung 
cancer and is implicated in its invasive character [2], while 
LPHN2 and 3 are upregulated or mutated in several types 
of metastatic cancer [3–5]. Stimulation of LPHN1 induces 
intracellular Ca2+ mobilisation and thus triggers significant 
exocytosis of neurotransmitters, which is crucial for 
normal neuronal function [6–7]. LPHN1 also plays an 
important role in cell surface interactions (reviewed in [1]). 
Exocytotic activity is also required for cytokine/growth 
factor release during myeloid cell haematopoiesis [8–11], 
especially when myeloid leukocytes undergo malignant 
transformation. Firstly, the energy resources of leukaemia 
cells are normally very limited [8–12] and lead to oxygen 
starvation. Therefore, the bone marrow vasculature plays 
a pivotal role in the survival of leukaemia cells, which 
induce angiogenesis by releasing vascular endothelial 
growth factor (VEGF) and other pro-angiogenic factors. 
Secondly, leukaemic cells produce and release interleukin 
6 (IL-6), which is necessary to support their own survival 
and proliferation [13]. These processes require efficient 
exocytosis. We therefore hypothesised that myeloid 
leukaemia cells may express LPHN1, a receptor that is 
able to convert cell-surface interactions into intracellular 
signals leading to activation of exocytosis. 
Here we report, for the first time, that LPHN1 
expression is clearly detectable at both RNA and 
protein level in human monocytic leukaemia (ML) 
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ABSTRACT
Acute myeloid leukaemia (AML) is a blood cancer affecting cells of myeloid 
lineage. It is characterised by rapid growth of malignant leukocytes that accumulate 
in the bone marrow and suppress normal haematopoiesis. This systemic disease 
remains a serious medical burden worldwide. Characterisation of protein antigens 
specifically expressed by malignant cells, but not by healthy leukocytes, is vital for 
the diagnostics and targeted treatment of AML. Here we report, for the first time, that 
the neuronal receptor latrophilin-1 is expressed in human monocytic leukaemia cell 
lines and in primary human AML cells. However, it is absent in healthy leukocytes. 
Latrophilin-1 is functional in leukaemia cells tested, and its biosynthesis is controlled 
through the mammalian target of rapamycin (mTOR), a master regulator of myeloid 
cell translational pathways. Our findings demonstrate that latrophilin-1 could be 
considered as a novel biomarker of human AML, which offers potential new avenues 
for AML diagnosis and treatment.
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cell lines (U937 and THP-1) and in primary human 
acute myeloid leukaemia (AML) cells. Treatment of all 
these leukaemia cells with the inflammatory mediator 
lipopolysaccharide (LPS) further upregulates LPHN1 
translation via mammalian target of rapamycin (mTOR, 
a master regulator of myeloid cell translation and growth 
[14]). When LPHN1 is stimulated by its high-affinity 
ligand [7], α-latrotoxin (LTX), this significantly increases 
LPS-induced IL-6 release from leukaemia cell lines and 
primary cells. In contrast, in healthy primary human 
leukocytes, LPHN1 expression is not detectable and is 
not induced by the mTOR activators LPS, SCF or anti-
Tim-3. We therefore conclude that LPHN1 is a novel 
pharmacoproteomic biomarker of human AML that offers 
new approaches to therapeutic targeting of this disease. 
RESULTS
LPHN1 expression and activity in human ML 
cell lines 
In order to investigate the possibility of LPHN1 
expression in human AML cells, we first used human ML 
cell lines, U937 and THP-1. Cells were stimulated for 
24 h with LPS, LTX or a combination of these ligands. 
LPS is a pathogen-associated molecular pattern shared by 
Gram-negative bacteria and is recognised by the Toll-like 
receptor 4 (TLR4), which is expressed by human myeloid 
cells [13]. LPS was chosen to avoid TLR4 activation 
by endogenous ligands (such as proteins released after 
dysfunctionalisation of mitochondria), which themselves 
induce the expression and release of IL-6 and other 
important factors required for leukaemia cell survival 
[15]. Using Western blot analysis, we found that U937 
cells constitutively expressed LPHN1 (Figure 1A) and the 
same pattern was observed in THP-1 cells (Figure 2A). 
In both U937 and THP-1 cells, LPHN1 expression levels 
were significantly increased (4-12-fold) by LPS, but not 
by LTX; when used in combination with LPS, LTX also 
did not significantly change LPHN1 levels compared to 
LPS alone (Figures 1A and 2A). However, whilst LTX 
alone did not stimulate IL-6 release, LTX combined with 
LPS induced the release of IL-6 that was 2 times greater 
than for LPS alone in both U937 and THP-1 human ML 
cells (Figures 1A and 2A). 
We also found that LPS, but not LTX, significantly 
activated the mTOR pathway: LPS augmented by 2-fold 
the activating phosphorylation of mTOR at S2448 and 
increased the phosphorylation of its substrate, p70 S6 
kinase 1 (p70 S6K1) at position T389. This was clearly 
observed in both cell lines (Figures 1B and 2B). 
Figure 1: Expression and activity of LPHN1 in U937 human ML cells. (A) U937 cells were exposed to 1 μg/ml LPS, 500 pM 
LTX or a combination of these two ligands for 24 h. Following cell lysis, IL-6 release was measured by ELISA, whilst LPHN1 protein levels 
were analysed by Western blotting. PC; positive control for LPHN1 (mouse brain extract). (B) Phospho-S2448 mTOR and phospho-T389 
p70 S6K1 were detected using ELISA and Western blotting, respectively. Western blot images show one experiment representative of six, 
all of which gave similar results. Data are the mean values ± SEM (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001.
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Since mTOR is a master regulator of myeloid cell 
translational pathways [14], it could be hypothesised 
that the mTOR pathway is responsible for LPS-induced 
upregulation of LPHN1 protein levels. We therefore 
exposed both U937 and THP-1 cells for 4 h to 1 μg/ml LPS 
with or without 1h pre-treatment with rapamycin (a highly 
specific mTOR inhibitor). We observed that 4-h exposure 
to LPS led to a moderate increase in LPHN1 expression 
in both U937 and THP-1 cells, which was less than the 
increase induced by 24 h stimulation and more pronounced 
in THP-1 versus U937 cells. In both cell lines, rapamycin 
fully blocked the expression of LPHN1 (Figure 3A and 
3B). Importantly, rapamycin did not affect the viability of 
the cells, as verified using MTS cell viability test (data not 
shown). In order to confirm the role of mTOR signalling 
in upregulation of LPHN1, we performed a similar 
experiment using another mTOR inhibitor, AZD2014 
[16]. AZD2014 did not affect cell viability as measured 
by cell viability assay (data not shown); however, in both 
U937 and THP-1 cells, AZD2014 obliterated expression of 
LPHN1 protein (Figure 3C and 3D).
Functional LPHN1 is expressed in human 
primary AML cells, but not in healthy leukocytes
Next, we asked whether functional LPHN1 is 
expressed in primary human AML cells. We exposed 
AML-PB001F primary human mononuclear blasts for 
24 h to LPS, LTX or a combination of these ligands. We 
found that LPS upregulated both mTOR activation and 
IL-6 release by these cells. LTX alone was ineffective, 
but in combination with LPS it significantly increased 
both mTOR activation and IL-6 exocytosis (Figure 4). 
In order to determine whether LPHN1 expression levels 
in AML-PB001F cells were also controlled through the 
mTOR pathway, we exposed these cells for 4 h to different 
mTOR activators: LPS, SCF or anti-Tim-3 antibody. We 
found that each stimulus led to a significant increase in 
the activating phosphorylation of mTOR (on S2448, 
Figure 5A), while the SCF-induced effect was stronger 
due to high levels of Kit receptor expression by these 
cells [17]. The magnitude of mTOR-dependent effects 
provoked by LPS, SCF and anti-Tim-3 in human AML 
cells observed here agrees well with previously published 
data [17]. Interestingly, all stimuli significantly induced 
LPHN1 expression, as shown by Western blot analysis 
(Figure 5A). 
Most importantly, when we tested healthy primary 
human leukocytes, they did not show any LPHN1 
expression (even after overexposure of Western blots). 
Furthermore, LPHN1 was also undetectable following 4 
or 24 h exposures of healthy leukocytes to LPS, SCF or 
anti-Tim-3 antibody (Figure 5B). 
To confirm the results based on protein expression, 
we then conducted quantitative real-time PCR (RT-PCR) 
to detect and quantify LPHN1 mRNA. These experiments 
demonstrated that LPHN1 mRNA is detected in THP-1 
cells and primary AML cells, but not in healthy primary 
human leukocytes (Figure 5C). Furthermore, we noted 
that LPS significantly increased the already high level of 
Figure 2: Effects of LPS and LTX on LPHN1 expression, IL-6 exocytosis and mTOR activity in THP-1 human ML 
cells. (A) THP-1 cells were exposed to 1 μg/ml LPS, 500 pM LTX or a combination of these two ligands for 24 h. Following cell lysis, 
LPHN1 protein levels were analysed by Western blot. IL-6 release was measured by ELISA. (B) Phospho-S2448 mTOR and phospho-T389 
p70 S6K1 were detected using ELISA and Western blot, respectively. Western blot images show one experiment representative of six, 
which gave similar results. Data are mean values ± SEM (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001.
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LPHN1 mRNA in THP-1 cells and primary AML cells. 
In contrast, even a 24 h exposure to LPS did not induce 
LPHN1 mRNA expression in primary healthy human 
leukocytes (Figure 5C).
Taken together, our findings demonstrate the 
regulated expression of the functional neuronal receptor 
LPHN1 in human AML cells, but not in healthy primary 
human leukocytes. This opens a new direction in research 
of malignant transformation and survival of cancerous 
white blood cells and the role of LPHN1 in these 
processes.
DISCUSSION
LPHN1 functions as an exocytosis promoter acting 
through calcium mobilisation/signalling machinery [1, 6, 
7]. The presence of regulated exocytosis is one of the main 
features of neurons and neuroendocrine cells, where this 
receptor is highly abundant. However, the requirement 
of exocytosis in malignant cells, in particular myeloid 
leukocytes, has not yet been investigated and there are no 
reports regarding a possible role of LPHN1 in leukaemia 
and pro-leukaemic haematopoiesis. 
We therefore considered the possibility of LPHN1 
protein expression in human leukaemia cells. Our studies 
demonstrate that resting ML cells from U937 and THP-
1 human cell lines clearly express LPHN1 mRNA and 
possess detectable amounts of functional LPHN1 protein. 
We also show that expression of functional LPHN1 
is dependent on the mTOR pathway. LTX, a specific 
LPHN1 agonist [3], significantly increased LPS-induced 
exocytosis of IL-6 in both cell lines. Since the production 
of IL-6 protein depends on mTOR [18], and the activity of 
the mTOR pathway was not upregulated by LTX in either 
cell line employed, it is evident that LTX triggers IL-6 
exocytosis rather than its biosynthesis. Wild type LTX 
used in our experiments is known to form Ca2+-permeable 
pores in the membrane of cells expressing toxin receptors 
[6], and such pores could potentially induce LPHN1-
independent exocytosis. However, LTX only inserts 
itself into the membrane after binding the receptor [6], 
and this interaction always stimulates LPHN1, leading to 
exocytosis [6, 7]. Indeed, in our experiments, the toxin 
stimulated secretion in LPHN1-expressing cells only 
(Figures 1, 2, 4). Furthermore, mutant LTXN4C, which 
does not form pores [7], induced similar exocytosis of 
Figure 3: Expression of LPHN1 in U-937 and THP-1 cells depends on mTOR. U-937 (A, C) and THP-1 (B, D) cells were 
exposed to 1 μg/ml LPS for 4 h with or without 1 h pre-treatment with 10 µM rapamycin (A, B) or AZD2014 (C, D). LPHN1 expression was 
then measured using Western blot analysis. Western blot images show one experiment representative of four, which gave similar results. 
Data are mean values ± SEM (n = 4). *p < 0.05; **p < 0.01; ***p < 0.001.
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IL-6 in THP-1/U-937 cells (data not shown), confirming 
the active role of LPHN1 in this secretion. Interestingly, 
LPHN1 expression is completely abolished when the cells 
are pre-treated with the mTOR inhibitors (rapamycin or 
AZD2014) before stimulation of U937 or THP-1 cells by 
LPS (Figure 3). This suggests that the process of LPHN1 
expression fully depends on the mTOR pathway. As 
shown in Figures 1B and 2B, both cell lines demonstrate 
a background activity of the mTOR pathway, which 
is further upregulated by LPS, and it is this additional 
activation of mTOR that brings about the substantial 
increase in the amount of expressed LPHN1 at 24 h. 
Clearly, ML cell lines differ from malignant 
leukocytes in vivo both in terms of biological activities 
and protein expression profiles. However, patient-derived 
primary human AML cells (we used primary AML-
PB001F mononuclear blasts obtained from leukaemia 
patients) do not differ from the two ML cell lines in 
respect of the easily detectable LPHN1 expression and 
its upregulation in response to mTOR stimuli (LPS, SCF 
and anti-Tim-3). Similarly, stimulation of the primary 
leukaemia cells with LTX leads to a substantial increase 
in the release of LPS-induced IL-6. On the other hand, 
unlike in the cell lines, LTX also upregulates LPS-induced 
mTOR-activating phosphorylation in the primary AML 
cells. Our observed effect is likely to be the result of low 
expression of the LPS receptor, TLR4, in the primary 
AML cells, as reported by their supplier. As a result of 
the lower TLR4 signalling, only some mTOR will be 
activated by LPS, while the majority of mTOR will still 
remain unphosphorylated and therefore subject to further 
phosphorylation through LPHN1-induced signalling. In 
cell lines, where the TLR4 expression levels are higher, 
there may not be sufficient scope for further activation 
of mTOR by LTX. This finding implies a functional 
integration of LPHN1 into the AML signalling machinery 
[13, 19]. Its possible functions are summarised in Figure 6.
One very important finding of this work is that 
primary healthy human leukocytes do not express any 
LPHN1. Furthermore, LPHN1 expression is not inducible 
by exposure of the healthy cells to any of the stimuli that 
show positive effects in AML cells: LPS, SCF or anti-
Tim-3. This clearly demonstrates that the expression of 
functional LPHN1 occurs specifically in leukaemia cells 
only. Quantitative RT-PCR experiments further confirm 
that healthy primary leukocytes do not possess detectable 
LPHN1 mRNA. This indicates that the change in the 
expression profile of this important receptor only takes 
place in leukocytes during or as a result of malignant 
transformation. The importance of LPHN1 to malignant 
leukocytes is evident: for their survival, these cells release 
certain growth factors and cytokines (for example, VEGF 
Figure 4: Effects of LPS and LTX on IL-6 exocytosis and mTOR activity in primary human AML cells. Primary human 
AML-PB001F cells were exposed to 1 μg/ml LPS, 500 pM LTX or a combination of these two ligands for 24 h. Following cell lysis, IL-6 
release into the medium and mTOR S2448-phosphorylation in cell lysates were measured by ELISA. Data are the mean values ± SEM 
(n = 6). *p < 0.05; **p < 0.01.
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and IL-6). This requires not only the presence of efficient 
exocytotic machinery, but also the means of controlling 
and stimulating exocytosis, for example, in response to 
leukocyte cell-surface interactions.
LPNH1 can, therefore, be further considered as a 
novel biomarker for AML diagnostics. Most existing 
leukaemia biomarkers are relative: they are expressed 
in both healthy and malignant cells, but their levels are 
higher in malignant cells; in contrast, LPHN1 is totally 
absent from healthy leukocytes and is thus an absolute 
biomarker of leukaemic cells. Furthermore, LPHN1 
could now be explored as a potential novel target for anti-
leukaemia therapy and drug delivery. For this purpose, it 
would be essential to identify a ligand that could bind and 
activate LPHN1 in leukaemia cells. Such a ligand would 
not only allow a full characterisation of the malignant 
transformation pathway, but would also provide a potential 
therapeutic target(s) to prevent LPHN1-induced exocytosis 
in leukaemia cells. The ligand of leukaemia LPHN1 could 
be a soluble factor circulating in blood plasma or it could 
be expressed on the surface of certain blood, endothelial 
or bone marrow cells. We previously characterised 
the natural LPHN1 ligand of nervous tissue (Lasso/
teneurin-2) [20]. However, in the current work we were 
unable to detect Lasso by Western blot in ML cell lines 
(THP-1 and U-937), primary healthy leukocytes or blood 
plasma obtained from healthy donors (data not shown). 
Future research will concentrate on the identification and 
isolation of peripheral ligand/s of leukaemic LPHN1. 
MATERIALS AND METHODS
Materials
All cell culture reagents were from Sigma (Suffolk, 
UK). Microtitre plates were obtained from Nunc (Roskilde, 
Denmark). LTX and LTXN4C were purified as previously 
described [6]. Mouse monoclonal antibodies to mTOR 
and β-actin and rabbit polyclonal antibodies against 
phospho-S2448 mTOR were from Abcam (Cambridge, 
Figure 5: Primary human AML cells but not healthy primary human leukocytes express LPHN1. (A, B) Primary AML-
PB001F cells (A) were exposed for 4 h and healthy human leukocytes (B) for 4 h or 24 h to 1 µg/ml LPS, 0.1 µg/ml SCF or 2 µg/ml 
anti-Tim-3. Following cell lysis, LPHN1 protein levels were analysed by Western blotting and phospho-S2448 mTOR was quantitated 
by ELISA. Control, mouse brain extract. (C) Quantitative RT-PCR was used to determine the levels of LPHN1 mRNA in THP-1 cells, 
primary human AML cells and primary healthy human leukocytes (PHL) prior to any treatment (0 h Con), after a 24 h incubation without 
stimulation (24 h Con), or after a 24 h stimulation with 1 μg/ml LPS (24 h LPS). Data are the mean values ± SEM (n = 4). N.d., not 
detectable; *p < 0.05; **p < 0.01. 
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UK). Antibodies against phospho-T389 and total p70 S6 
kinase 1 (p70 S6K1) were obtained from Cell Signalling 
Technology (Danvers, MA USA). Goat anti-mouse and goat 
anti-rabbit fluorescent dye-labelled antibodies were from Li-
Cor (Lincoln, Nebraska USA). ELISA-based assay kits for 
the detection of IL-6, was from R&D Systems (Abingdon, 
UK). The polyclonal rabbit anti-peptide antibody PAL1 
against LPHN1 and polyclonal mouse antibody dmAb 
against Lasso/teneurin-2 were previously described [20, 21]. 
Human SCF [22] and anti-Tim-3 monoclonal antibody [23] 
were a kind gift of Dr. Luca Varani.
THP-1 and U937 human myeloid cells
THP-1 human myeloid leukaemia monocytic 
macrophages and U937 human leukaemia monocytes were 
obtained from the European Collection of Cell Cultures 
(Salisbury, UK). Cells were cultured in RPMI 1640 media 
supplemented with 10% foetal calf serum, penicillin (50 
IU/ml) and streptomycin sulphate (50 µg/ml).
Primary human AML cells 
Primary human AML mononuclear cells (AML-
PB001F, newly diagnosed/untreated) were purchased from 
AllCells (Alameda, CA, USA) and handled in accordance 
with manufacturer’s instructions. Cells from four different 
patients were used in reported experiments.
Primary human leukocytes from healthy donors
Primary human leukocytes were obtained from 
blood buffy coat (prepared from healthy donors) 
purchased from the National Health Blood and 
Transfusion Service (NHSBT, UK) following ethical 
approval (REC reference: 12/WM/0319) [17, 24]. 
Mononuclear-rich leukocytes were obtained by Ficoll-
density centrifugation according to the manufacturer’s 
(GE Healthcare Life Sciences) protocol. Cell numbers 
were determined using a haemocytometer and diluted 
accordingly with HEPES-buffered Tyrode’s solution 
before treatment, as indicated.
Figure 6: Functional integration of LPHN1 into AML cell signalling machinery. LPHN1 transcription and translation 
is induced in AML cells. LPS upregulates LPHN1 transcription and triggers TLR4-mediated activation of the mTOR pathway, which 
increases translation of LPHN1 and IL-6. In addition, both LPS (through TLR4 and Btk) and LTX (through LPHN1 and Gq) activate 
PLC, which produces IP3, leading to release of Ca
2+ from the ER. Increased cytosolic Ca2+ triggers exocytosis of IL-6. Abbreviations: Btk, 
Bruton’s tyrosine kinase; MD, myeloid differentiation factor 88; TAP, Toll-like receptor intracellular TIR domain-associated protein; PI-3K, 
phosphatidylinositol 3-kinase; PDK, phosphatidylinositol-3-phosphate-dependent kinase; IP3, inositol trisphosphate; PLC, phospholipase 
C; Gq, Gαq subunit of a heterotrimeric G protein; TSC1/TSC2, tuberous sclerosis proteins 1 and 2; eIF4E, eukaryotic translation initiation 
factor 4E; p70S6K1, mTOR-dependent S6 kinase 1; ER, endoplasmic reticulum. Symbols: ←activation; ├ inactivation; dotted lines, 
indirect process involving multiple steps.
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Western blot analysis
The levels of LPHN1, total and phospho-T389 p70 
S6K1 as well as Lasso/teneurin 2 were determined by 
Western blot analysis, as previously described [17, 23]. 
Fluorescently labelled antibodies (Li-Cor) were used 
according to the manufacturer’s protocol to visualise the 
proteins of interest using an Odyssey imaging system (Li-
Cor). Western blot data were subjected to quantitative 
analysis using the Odyssey software and values were 
normalised against respective β-actin bands.
Quantitative real-time reverse transcription 
PCR (qRT-PCR)
Total RNA was extracted using the Illustra RNAspin 
Midi RNA isolation kit (GE Healthcare) and quantified 
spectroscopically with a Nanodrop 2000® (Thermo 
Scientific). cDNA was synthesised using Transcriptor 
First Strand cDNA Synthesis Kit (Roche), which was 
performed in accordance with the manufacturer’s protocol. 
Relative quantification of LPHN1 mRNA was performed 
using SYBR Green I Master reaction mix (Roche) and a 
LightCycler 480 (Roche). The house-keeping gene β-actin 
was used as a reference gene. The following primers 
were used at a final concentration of 0.5 µM: LPHN1, 
5′-AGCCGCCCCGAGGCCGGAACCTA-3′ and 5′-AGG 
TTGGCCCCGCTGGCATAGAGGGAGTC-3′; Actin, 5′-T 
TCGCGGGCGACGATGC-3′ and 5′-GGGGCCACACGC 
AGCTCATT-3′.
PCR reactions began with incubation at 95ºC for 3 
min 30 s, then proceeded for 45 cycles of 95ºC for 10 
s, 60ºC for 20 s and 72°C for 10 s. Fluorescence level 
was detected at 80°C in each cycle. A final elongation step 
was held at 72°C for 5 min. Raw fluorescence data were 
analysed using LinRegPCR quantitative PCR data analysis 
programme [25]. Amplified products were examined on 
1.5% agarose gel containing ethidium bromide.
Detection of phospho-S2448 mTOR in cell lysates 
by ELISA
Phosphorylation of mTOR was monitored using 
ELISA assays as recently described [15]. Briefly, ELISA 
plates were coated with mouse anti-mTOR antibodies and 
blocked with 2% BSA. Cell lysates were then added to the 
wells and incubated with agitation at room temperature for 
2 h. After washing with TBST buffer, anti-phospho-S2448 
mTOR antibody was added and plates were incubated 
with agitation for 2 h at room temperature. Plates were 
then washed with TBST buffer and incubated with 1:1000 
HRP-labelled goat anti-rabbit IgG in TBST buffer. 
After washing with TBST, bound secondary antibodies 
were detected by the peroxidase reaction (ortho-
phenylenediamine/H2O2). 
Detection of exocytosed IL-6
Concentrations of IL-6 released into cell culture 
media were analysed by ELISA (R&D Systems assay kit) 
according to the manufacturer’s protocol.
Cell viability assay
Cell viability was analysed using the Promega 
(Southampton, UK) MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
assay kit according to the manufacturer’s protocol.
Statistical analysis
Each experiment was performed 3–6 times and 
statistical analysis was conducted using ANOVA test with 
Bonferroni correction.
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